Targeting PI3 kinase in cancer.

  title={Targeting PI3 kinase in cancer.},
  author={Todd M. Bauer and Manish R Patel and Jeffrey R. Infante},
  journal={Pharmacology & therapeutics},
The PI3K/Akt/mTOR pathway is the most frequently known activated aberrant pathway in human cancers. Pathologic activation can occur at multiple levels along the signaling pathway by a variety of mechanisms, including point mutations, amplifications, and inactivation of tumor suppressor genes. This pathway is also a known resistance pathway, as it can be activated by both receptor tyrosine kinases and other oncogenes. mTOR inhibitors were the first targeted molecules in this pathway, and have… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 34 extracted citations

Similar Papers

Loading similar papers…